SUBSCRIBE
SUBSCRIBE
News   FDA

US OKs Novartis Corporation Gleevec to Reduce Recurring Cancer

December 22, 2008 | 
1 min read

WASHINGTON, Dec 19 (Reuters) - U.S. health regulators have approved Novartis’ drug Gleevec to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday.

FDA Approvals
MORE ON THIS TOPIC
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac
Contemporary collage with a running clock and an arrow. Planning and time management concept.
Regulatory
FDA Outlines Accelerated Review Guidelines in Waning Days of Biden Administration
December 6, 2024
 · 
3 min read
 · 
Annalee Armstrong